Physician profile
Maayan E Keshet
NPI 1053588632
$28,830.93
in general payments reported to CMS, 2019-2025
33 companies · $3,700 in 2025
The $3,700 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,283 · 2020: $2,308 · 2021: $4,589 · 2022: $11K · 2023: $2,224 · 2024: $3,972 · 2025: $3,700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,801 · Education: $95.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,801.39 |
| Education | $95.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $6,050.02 | 2019-2022 | |
| Sight Sciences, INC. | $4,790.51 | 2021-2024 | Tearcare System, Omni Surgical System |
| Alcon Vision LLC | $3,288.31 | 2019-2025 | Clareon, Centurion, Clareon Panoptix Pro |
| Allergan, INC. | $2,308.69 | 2019-2022 | |
| Regeneron Pharmaceuticals, INC. | $2,300.00 | 2022 | |
| Bausch & Lomb Americas INC. | $1,868.18 | 2022-2025 | Envista Mx60 Iol, Miebo, Xiidra |
| Harrow Eye, LLC | $1,268.36 | 2024-2025 | Vevye |
| Abbvie INC. | $1,111.86 | 2022-2025 | |
| Oyster Point Pharma, INC. | $924.91 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $840.77 | 2019-2025 | Cequa, Xelpros |
| Kala Pharmaceuticals, INC. | $716.78 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $657.14 | 2019-2025 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Glaukos Corporation | $403.04 | 2023-2025 | Idose, Istent Infinite, Idosetr |
| Novartis Pharmaceuticals Corporation | $378.46 | 2019-2023 | |
| New World Medical,INC. | $329.51 | 2021-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $325.04 | 2021-2025 | Acthar |
| Tarsus Pharmaceuticals, INC. | $240.74 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $227.09 | 2019-2021 | |
| Rxsight INC | $179.02 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Dompe US, INC. | $137.61 | 2019-2025 | Oxervate |
| Amgen INC. | $110.78 | 2024-2025 | Tepezza |
| Thea Pharma INC. | $88.05 | 2023 | Iyuzeh |
| Biotissue Holdings INC. | $58.68 | 2021-2022 | |
| Optos, INC. | $33.67 | 2019 | |
| Shire North American Group INC | $32.62 | 2019 | |
| Ocular Therapeutix, INC. | $26.10 | 2023 | Dextenza |
| Ivantis, INC | $25.98 | 2021 | |
| Astellas Pharma US INC | $24.09 | 2025 | Izervay |
| Coopervision INC. | $22.48 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Horizon Therapeutics Plc | $15.91 | 2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $15.39 | 2020 | |
| Rayner Intraocular Lenses Limited | $11.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maayan Keshet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.